VACCINATION

Strategic Advisory Group

The EAP Vaccination Strategic Advisory Group (VSAG) consists of representatives from all European regions, who are involved in their national immunisation programmes, with the intention to build an effective and interactive network.

Hans Jürgen Dornbusch, MD

Chair

Hans Jürgen Dornbusch, MD

Chair

 

Dr. Dornbusch has devoted his career to paediatric infectious diseases, with a special focus on early detection of infections in immunocompromised children, as explored in his 2009 habilitation. He holds a teaching position at the Medical University of Graz, has authored numerous publications, and frequently lectures on infectious diseases and vaccinology. Currently, he serves as head of the vaccination board of the Austrian Society for Paediatrics and Adolescent Medicine.

Additionally, he earned his Ph.D. at the Medical University of Silesia, Katowice, and has conducted significant research on paediatric endocrinology, diabetes, rare diseases, and the role of nutrition in public health.

ABOUT

VACCINATION

The major goal of the EAP VSAG is to support activities leading to better Harmonisation of Vaccination programmes within the European region and to optimal Coverage with recommended vaccines.


The EAP VSAG meets twice a year for discussion of the current situation of immunisation in Europe. Data are collected mainly by means of surveys. Major topics comprise implementation of recommended vaccines, national monitoring of vaccination coverage, measures to increase vaccination coverage, approach to vaccine refusal / “individualization”, shortages in vaccine supply, and others.


The EAP VSAG seeks collaboration with WHO, ECDC, EPA and other European organizations interested in the field of Vaccinology, in order to optimize its efforts to achieve the goals mentioned above.


The EAP VSAG supports the ambitious WHO European Vaccine Action Plan 2015-2020 with its vision: A European Region free of vaccine-preventable diseases, where all countries provide equitable access to high-quality, safe, affordable vaccines and immunization services throughout the life course.

Agendas

Your Enquiries Are Welcome

We will respond to you by Email

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative: